Zydus Cadila bronchospasm drug Albuterol gets USFDA approval
This medicine is used to treat and to prevent bronchospasm.
Ahmedabad: Drugmaker, Zydus Cadila, has recently announced that the company has received final approval from the US Food & Drug Administration (USFDA) to market Albuterol Tablets (US RLD: Proventil Tablets) in the strengths of 2 mg and 4 mg.
Albuterol is a bronchodilator. It helps open up the airways in your lungs to make it easier to breathe.
This medicine is used to treat and to prevent bronchospasm.
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 310 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Cadila Solifenacin Succinate tablets get USFDA okay to treat overactive bladder
The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.